ArticleCureus2025
Hyperbaric Oxygen Therapy for Branch Retinal Artery Occlusion: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal artery occlusion (RAO) is an ophthalmic emergency primarily caused by systemic cardiovascular diseases. Central RAO (CRAO) may lead to severe visual loss, whereas branch retinal artery occlusion (BRAO) is associated with more benign symptoms and often resolves with less severe visual dysfunction. The etiopathogenesis of RAO is similar to that of ischemic stroke. It involves sudden occlusion of the retinal artery, leading to ischemia of the inner layers of the retina, retinal infarction, permanent damage to sensory cells, and resultant irreversible loss of vision. Although small-sample studies on the treatment of CRAO are available, only a few case series and reports on the efficacy of hyperbaric oxygen therapy (HBOT) in BRAO have been published. In this case series, we aimed to evaluate the effectiveness of HBOT in improving visual acuity in patients with BRAO based on an analysis of selected case reports. Patients underwent HBOT at 5, 36, and 48 hours after the onset of ocular symptoms, and visual acuity improved both quantitatively and qualitatively. HBOT has beneficial effects on the final visual acuity of patients following an episode of BRAO and may be a rescue treatment for early-stage BRAO, particularly when reperfusion is still feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.